Incyte Corporation (INCY)
Summary
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS settlement boosts investor sentiment.
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?
Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Incyte: New Catalysts Support Another Leg Higher
Incyte Corporation remains a strong long pick, with a maintained 'Buy' rating and a 40% upside to a $159.5/share price target. Recent catalysts include a positive CHMP opinion for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding INCY's product portfolio and reducing Jakafi concentration risk. Q1 2026 results showed robust diversification: revenues up 21% YoY, adjusted EPS up 56% YoY, and ex-Jakafi sales up 63% YoY.
Incyte Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 4,486 | $375,664.07 | $513,924.23 | $138,260.16 | 36.8% |
 Dodge & Cox Dodge & Cox Funds | 14.86M | $1.18B | $1.7B | $521.47M | 44.14% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 77,085 | $7.61M | $8.83M | $1.22M | 15.99% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 790 | $69,410.96 | $90,695.4 | $21,284.44 | 30.66% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 1,969 | $188,509.08 | $226,269.21 | $37,760.13 | 20.03% |
Incyte Corporation (INCY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Incyte Corporation ever had a stock split?
Incyte Corporation Profile
| Biotechnology Industry | Healthcare Sector | William J. Meury CEO | NASDAQ (NGS) Exchange | 45337C102 CUSIP |
| US Country | 2,844 Employees | - Last Dividend | 1 Sep 2000 Last Split | 4 Nov 1993 IPO Date |
Overview
Incyte Corporation is a prominent biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics. With a broad interest in hematology/oncology and inflammation and autoimmunity sectors, Incyte operates both within the United States and on an international scale. Originally founded in 1991 and known as Incyte Genomics Inc., the company underwent a name change to Incyte Corporation in March 2003. It has established a formidable presence in the pharmaceutical industry, not only through the inception of proprietary drugs but also via strategic collaborations and in-license agreements with other leading biotech entities such as Novartis, Lilly, Agenus, Merus, MacroGenics, Syndax, and China Medical System Holdings Limited. Headquartered in Wilmington, Delaware, Incyte holds a pivotal role in pushing forward the boundaries of medical research and patient care in critical disease areas.
Products and Services
- JAKAFI (ruxolitinib)
A cornerstone in Incyte's portfolio, JAKAFI is approved for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. Its mechanism targets aberrant signaling pathways to curb disease progression.
- MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab)
Designed for patients with relapsed or refractory diffuse large B-cell lymphoma; a testament to Incyte's commitment to addressing unmet needs in oncology.
- PEMAZYRE (pemigatinib)
Acts as a fibroblast growth factor receptor kinase inhibitor, targeting oncogenic drivers in various liquid and solid tumor types, showcasing Incyte's innovative approach in targeted cancer therapy.
- ICLUSIG (ponatinib)
Approved for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia, providing a targeted therapeutic option for these hematologic cancers.
- ZYNYZ (retifanlimab-dlwr)
This drug is deployed in the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma, underscoring the company's dedication to rare oncology indications.
- OPZELURA cream
Marketed for the treatment of atopic dermatitis, this offering diversifies Incyte's portfolio into the dermatological field, addressing a common yet challenging chronic skin condition.
In addition to these marketed products, Incyte's clinical stage pipeline showcases a robust commitment to innovation through a variety of compounds under development, including retifanlimab for additional cancers, axatilimab for chronic GVHD, and a range of molecules designed to tackle solid tumors. The depth and breadth of Incyte's clinical research reflect its continuous pursuit of therapeutic advances to improve patient outcomes in areas of significant unmet medical need.
